AstraZeneca

19 Januari 2022 08:29

Imfinzi plus tremelimumab demonstrated unprecedented survival in 1st-line unresectable liver cancer with 31% of patients alive at three years

Positive results from the HIMALAYA Phase III trial showed a single priming dose of tremelimumab added to Imfinzi demonstrated a statistically significant and clinically meaningful improvement in overall survival versus sorafenib as a 1st-line treatment for patients with unresectable hepatocellular carcinoma who had not received prior systemic therapy and were not eligible for localised treatment.

17 Januari 2022 08:10

Enhertu granted Priority Review in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen

AstraZeneca and Daiichi Sankyo have received notification of acceptance of the supplemental Biologics License Application (sBLA) of Enhertu (trastuzumab deruxtecan) for the treatment of adult patients in the US with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen. The application has also been granted Priority Review.

14 Januari 2022 08:00

Freja Annamatz ny presschef för AstraZeneca i Sverige

AstraZeneca meddelar i dag att man har anställt Freja Annamatz som presschef för bolagets svenska verksamhet. Hon börjar 1 April 2022 och kommer att rapportera till kommunikationsdirektör Jacob Lund.

13 Januari 2022 08:33

AstraZeneca aims to redefine liver, biliary tract and prostate cancer treatment with practice-changing Imfinzi and Lynparza data at ASCO GI and GU

AstraZeneca will present new data in liver, biliary tract and prostate cancers illustrating its ambition to revolutionise cancer care at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) and the 2022 ASCO Genitourinary Cancers Symposium (ASCO GU).

13 Januari 2022 08:29

AstraZeneca and Scorpion Therapeutics enter agreement to discover, develop and commercialise novel cancer treatments against ‘undruggable’ targets

AstraZeneca has signed a collaboration agreement with Scorpion Therapeutics to discover, develop and commercialise precision medicines against previously hard-to-target cancer proteins, with the potential to transform oncology treatment.
The new collaboration focuses on a class of proteins called transcription factors, which control gene expression and can regulate important cellular processes

13 Januari 2022 08:26

New Vaxzevria data further support its use as third dose booster

Positive results from a preliminary analysis of an ongoing safety and immunogenicity trial (D7220C00001) showed that Vaxzevria (ChAdOx1-S [Recombinant]), when given as a third dose booster, increased the immune response to Beta, Delta, Alpha and Gamma SARS-CoV-2 variants, while a separate analysis of samples from the trial showed increased antibody response to the Omicron variant.

7 Januari 2022 08:01

AstraZeneca and Neurimmune sign exclusive global collaboration and licence agreement to develop and commercialise NI006

Alexion, AstraZeneca’s Rare Disease group, has entered into an exclusive global collaboration and licence agreement with Neurimmune AG for NI006, an investigational human monoclonal antibody currently in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM).

5 Januari 2022 08:19

Transfer of global rights for Eklira and Duaklir to Covis Pharma completed

AstraZeneca has completed the transfer of its global rights to Eklira (aclidinium bromide), known as Tudorza in the US, and Duaklir (aclidinium bromide/formoterol) to Covis Pharma Group (Covis Pharma).

29 December 2021 08:02

AstraZeneca and Ionis close agreement to develop and commercialise eplontersen

AstraZeneca has closed a global development and commercialisation agreement with Ionis Pharmaceuticals, Inc. (Ionis) for eplontersen, formerly known as IONIS-TTR-LRX.

23 December 2021 08:07

Vaxzevria significantly boosted antibody levels against Omicron

AstraZeneca’s Vaxzevria (ChAdOx1-S [Recombinant]) significantly boosted levels of antibodies against the Omicron SARS-CoV-2 variant (B.1.1.529) following a third dose booster, according to data from a new laboratory study.

23 December 2021 08:02

Evusheld long-acting antibody combination retains neutralising activity against Omicron variant in studies from Oxford and Washington Universities

AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination for the prevention of COVID-19, retains neutralisation activity against the Omicron SARS-CoV-2 variant (B.1.1.529), according to new authentic ‘live’ virus neutralisation data from both University College Oxford, UK and Washington University School of Medicine, St. Louis, US.

21 December 2021 08:14

Ultomiris accepted for FDA Priority Review for gMG

The supplemental Biologics License Application (sBLA) for Ultomiris (ravulizumab-cwvz) in adults with generalised myasthenia gravis (gMG) has been accepted for Priority Review by the US Food and Drug Administration (FDA).

Nyhetsarkiv